China now accounts for a large share of the world's new oncology drugs and leads the world in CAR-T clinical trials. For a growing number of patients, the treatment that matches their tumour is available in Shanghai or Beijing years before it reaches their own pharmacy. We explain what exists, whether it fits your diagnosis, and how patients legally access it.
Four structural reasons, not a fad. Each one is a reason the gap between China and the rest of the world persists.
Drugs developed in China often reach Chinese patients 2–3 years before they are filed or launched elsewhere.
Including the first CAR-T therapy approved anywhere for a solid tumour, plus Claudin 18.2 and other targets Western programmes approached cautiously.
Cell therapy slots are available within days rather than months, with no insurer pre-authorisation step in the way.
Commercial CAR-T in China runs roughly ¥1.0–1.3 million including hospitalisation, against US pathways commonly quoted at several times that.
This boundary is the whole point of the service. It is also what keeps patients out of legal trouble.
A free, no-registration check. Select your cancer type and biomarker to see which treatments are approved in China, and whether they are already available where you live.
Five stages, from your first enquiry to follow-up care back home.
Pathology report, most recent scans, biomarker results (EGFR, ALK, CLDN18.2, PD-L1 and so on) and a full treatment history. Completeness here determines everything downstream.
A Chinese specialist reviews the translated dossier and gives an opinion on whether you are a candidate. This happens before you book anything.
Hospitals issue the documentation needed for a medical (S2) visa. Plan for weeks, not days — CAR-T alone typically needs 6–8 weeks in country across two trips.
Bilingual case management, direct hospital billing at official price schedules, and a same-language companion at key consultations.
You receive translated discharge summaries for your home oncologist, who stays responsible for your ongoing care.
Particularly where the matching drug is approved in China and unavailable or delayed at home.
Where a CAR-T product exists but the domestic pathway is unaffordable or uninsured.
Small biomarker-defined populations where China's development speed has produced the only targeted option.